Search

Bromopyruvate

Elacridar

In many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacridar was not listed on GSK's product pipeline. … Elacridar (GW120918) is an oral bioenhancer that targets multiple drug resistance in tumors.

Iodoxamic acid

Radiopaque medium used in the diagnosis of gall bladder & bile duct diseases, usually as meglumine salt.

Platinum

Platinum is under investigation for the treatment of Metastatic Breast Cancer, Non-small Cell Lung Cancer, Gastric Large Cell Neuroendocrine Carcinoma, Colorectal Large Cell Neuroendocrine Carcinoma, and

Sulfisoxazole

A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.

Peptide YY (3-36)

Peptide YY (3-36), a synthetic human PYY 3-36, is a compound being evaluated for the treatment of obesity. It reduces appetite and increases satiety in obese patients.

Incadronic acid

[A14426,A14431,A14427,A202769] Incadronic acid was first described in the literature in 1991.[A202289] … Along with being investigated to treat hypercalcemia of malignancy,[A202862] it has also been investigated in the treatment of myeloma, leukemia, and other cancers.

Elacytarabine

Elacytarabine is designed to overcome this limitation and has shown considerable uptake in solid tumour cells. … Elacytarabine is a fatty acid derivative of [cytarabine], an approved cytotoxic cancer drug. Cytarabine has limitations such as minimal uptake in solid tumours and is only used to treat leukaemia.

Malic acid

Malic acid has been used in trials studying the treatment of Xerostomia, Depression, and Hypertension.

AC-100

It is being developed by Acologix, Inc. … AC-100 is a novel synthetic peptide derived from an endogenous human protein produced by bone and dental cells (a fragment from matrix extracellular phosphoglycoprotein).